Bullous Pemphigoid

Patients with bullous pemphigoid experienced increases in cardiovascular mortality risk at 1, 3 and 5 years compared with matched controls, according to a study.

Steroid alternatives should be considered for patients with bullous pemphigoid, who are most likely to be treated with oral prednisolone, according to a study.

A multi-continental meta-analysis showed high mortality rates for patients with bullous pemphigoid.

Patients with autoimmune bullous diseases often experience negative impacts on their sexual quality of life, according to a poster presented at the American Academy of Dermatology virtual meeting.

Quality of life is impaired with negative psychological health outcomes in patients with immunobullous dermatoses, and systemic corticosteroids may increase these risks, according to a poster presentation.

Dipeptidyl peptidase-4 inhibition to treat type 2 diabetes was associated with an elevated risk for bullous pemphigoid, according to a study.

Rituximab contributed to reaching complete remission and reduced steroid use in patients with bullous pemphigoid, but did not increase overall survival, according to a poster presented at the American Academy of Dermatology virtual meeting.

The skin condition bullous pemphigoid may be more likely to develop in adults with type 2 diabetes who use DPP-IV inhibitors vs. those who do not use the medication, especially if they also use spironolactone or have dementia, according to findings published in the Journal of Diabetes and its Complications.